Glucocorticoid treatment does not impact adult height in girls with NCCAH
Women diagnosed with non-classical congenital adrenal hyperplasia during childhood or adolescence do not typically reach their target height, but this is not related to glucocorticoid treatment duration and dose, research shows.
New light shed on genetic landscape of SGA children who remain short
Genetic variations in genes regulating the growth plate appear to play a “central role” in the aetiology of persistent short stature among children born small for gestational age, report researchers from the Czech Republic.
Novel GHR variants may hold clues to treatment targets for short stature
Researchers have identified two naturally occurring, dominant-negative variants in the growth hormone receptor gene that act via the same molecular mechanism and contribute to the nonclassical growth hormone insensitivity phenotype.
Suicidality common hospitalisation cause for gender-variant young people
Suicidality or self-harm is a frequent cause of hospital admission among gender variant/diverse young people, report researchers.
Real-world data support early rhGH initiation for SGA children
Observational data confirm that children born small for gestational age achieve the best growth outcomes if they start treatment with recombinant human growth hormone as young as possible.
High-dose semaglutide triggers weight loss in adolescents with obesity
A weekly injection of a high dose of semaglutide results in substantial weight loss among adolescents with obesity, show the STEP TEENS trial findings.
Wide range of neurological issues in paediatric hyperinsulinism/hyperammonaemia syndrome
Neurodevelopmental disorders are frequent and diverse in children with hyperinsulinism/hyperammonaemia syndrome caused by a GLUD1 mutation, a study shows.
Multigene sequencing detects alterations in up to one in six children with ISS
A multigene sequencing panel has successfully identified one or more gene variants in up to one in six children with idiopathic short stature, researchers report in Endocrine Connections.
rhGH therapy does not impact lifetime IGF-1 exposure in SGA children
Years of treatment with recombinant human growth hormone does not increase the cumulative lifetime exposure to insulin-like growth factor-1 above the population average in children born small for gestational age, a study shows.
PEGylated weekly rhGH promising in idiopathic short stature
A weekly injectable PEGylated recombinant human growth hormone gives significantly better height outcomes than no treatment in children with idiopathic short stature, shows a phase 2 trial.